What is the recommended dose, maximum limits, and safety precautions for diclofenac aqueous injection in pediatric patients?

Diclofenac Aqueous Injection in Pediatrics

Safety and effectiveness of diclofenac injection in pediatric patients have not been established, and its use is not recommended in this population. 1

FDA-Approved Status and Safety Profile

The FDA drug label explicitly states that "safety and effectiveness in pediatric patients have not been established" for diclofenac injection. 1 This represents a critical regulatory gap that should guide clinical decision-making, as there is no approved pediatric indication for intravenous or intramuscular diclofenac formulations.

Evidence from Pediatric Research

Despite the lack of FDA approval, research studies have explored diclofenac use in children:

Dosing Information from Research Studies

• Intravenous dosing: A pharmacokinetic meta-analysis recommended 0.3 mg/kg as a single dose for children aged 1-12 years to achieve equivalent drug exposure to adult dosing. 2

• Intramuscular dosing: An observational study used approximately 2 mg/kg IM for antipyresis in febrile children over 12 months of age, with effective fever reduction occurring at an average of 69 minutes post-injection. 3

• Oral/rectal dosing for comparison: Research suggests 1 mg/kg orally or 0.5 mg/kg rectally for children aged 1-12 years. 2

Safety Considerations from Research

A Cochrane systematic review found that serious adverse reactions to diclofenac occurred in fewer than 0.24% of children treated for acute pain, with adverse event types similar to those in adults. 4 However, this evidence primarily reflects oral and rectal formulations used perioperatively, not injectable formulations.

Critical Safety Warnings for Pediatric Use

Fetal and neonatal toxicity concerns: The FDA label emphasizes that NSAIDs including diclofenac can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction. 1 While this specifically addresses pregnancy, it underscores the vulnerability of developing cardiovascular and renal systems to NSAID effects.

Specific Contraindications and Precautions

• Renal function monitoring: Elderly patients and those with impaired renal function face greater risks, suggesting similar caution is warranted in pediatric patients with developing renal systems. 1

• Gastrointestinal risks: NSAIDs carry significant GI toxicity risks that may be difficult to monitor in younger children. 1

• Drug interactions: Concomitant use with methotrexate, cyclosporine, other NSAIDs, or pemetrexed increases toxicity risks. 1

Alternative Pediatric Analgesic Options

For postoperative pain management in children, established guidelines recommend: 5

• Intravenous NSAIDs with established pediatric dosing:

  • Ketorolac: 0.5-1 mg/kg (max 30 mg) as single intraoperative dose, or 0.15-0.2 mg/kg (max 10 mg) every 6 hours for maximum 48 hours 5
  • Ketoprofen: 1 mg/kg every 8 hours 5
  • Ibuprofen IV: 10 mg/kg every 8 hours 5

• Rectal diclofenac: 0.5-1 mg/kg every 8 hours (when oral/IV NSAIDs unavailable) 5

Clinical Recommendation

Given the absence of FDA approval, lack of established safety data for injectable formulations, and availability of alternative NSAIDs with established pediatric dosing, diclofenac injection should not be used in pediatric patients. 1 If NSAID therapy is required, use agents with proven pediatric safety profiles such as ketorolac, ibuprofen IV, or ketoprofen as outlined in established pediatric pain management guidelines. 5